First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Inclusion criteria: * Personally signed informed consent document. * Male or female, age ≥18 years. * Relapsed or refractory ROR1+ malignancies * ECOG performance status ≤2. * Adequate organ function. * Bilirubin ≤1.5 x ULN (unless Gilbert's syndrome). * AST and ALT ≤2.5 x ULN (if no hepatic CLL or MCL), or AST and ALT ≤5 x ULN (if hepatic CLL or MCL). * APTT and PT ≤1.5 x ULN. * ANC ≥0.5 x 10\^9 /L (without growth factors) and platelets ≥ 30 x 10\^9 /L (without transfusion). * Serum creatinine ≤2 x ULN. * Estimated creatinine clearance ≥30 mL/min. * In females of childbearing potential, a negative serum pregnancy test. * For both males and females, willingness to use adequate contraception. * Willingness and ability to comply with study procedures. Exclusion Criteria: * Richter's transformation. * CNS or leptomeningeal active disease. * High tumour bulk as defined in the protocol. * Allogeneic or autologous organ transplant within prior 6 months. * Uncontrolled autoimmune haemolytic anaemia or idiopathic thrombocytopenic purpura within 8 weeks of screening. * Clinically significant neurological disease. * Clinically significant cardiovascular disease or ECG abnormalities. * Severe chronic lung disease. * Positive test at Screening for HIV, hepatitis B or hepatitis C infection. * Any other concurrent cancer or cancer treatments. * Uncontrolled ongoing infection * Recent major surgery * Concurrent participation in another clinical trial, or experimental therapy…